Aerie Pharmaceuticals Logo

News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation – January

OIS Glaucoma Innovation Summit

OIS Retina Innovation Showcase

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 22, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer
An accomplished leader Brings a depth and breadth of commercial, business development, and portfolio strategy experience DURHAM, N.C. --(BUSINESS WIRE)--Dec. 16, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the
View HTML
Toggle Summary Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions
Agreement includes Europe , Commonwealth of Independent States countries, China , India , parts of Latin America and the Oceania countries DURHAM, N.C. --(BUSINESS WIRE)--Dec. 7, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Aerie and Santen have entered into an
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 9, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
TOP